VEEVA SYSTEMS INC (VEEV)
SEC filings, insider trading & institutional ownership from EDGAR.
Veeva Systems is the leading provider of industry cloud solutions for the global life sciences industry, offering cloud software, data, and business consulting services designed for the strategic needs of pharmaceutical, biotechnology, and medical device and diagnostics companies across their research and development (R&D) and commercialization functions. Its offerings are organized into two major product families: Veeva Development Cloud, which includes application suites for clinical, regulatory, quality, and safety functions—such as Veeva Vault Clinical, Veeva Clinical Data Management Suite (CDMS), Veeva Clinical Operations Suite, Veeva Vault RIM, Veeva Vault Safety, and Veeva Vault Quality—all built on its proprietary Veeva Vault platform to streamline end-to-end product development and regulatory compliance; and Veeva Commercial Cloud, which supports sales, medical affairs, and marketing functions through software like Veeva CRM, Veeva Vault PromoMats, Veeva Vault Medical, and Veeva Crossix, along with data offerings including Veeva OpenData, Veeva Link, and Veeva Compass that provide healthcare provider and patient data for customer engagement and analytics. The company also extends its content and data management capabilities to the consumer products and chemical (CP&C) industries through applications such as Veeva QualityOne, Veeva RegulatoryOne, and Veeva Claims.
Beyond software, Veeva provides strategic consulting through Veeva Consulting and professional services including implementation, systems integration, training, and managed services, often working alongside systems integrator partners like Accenture, Cognizant, and Tata Consultancy Services. As of January 31, 2023, Veeva served 1,388 customers, ranging from large global pharmaceutical and biotechnology companies such as Bayer, Boehringer Ingelheim, Eli Lilly, Gilead Sciences, Merck Sharp & Dohme, and Novartis, to emerging growth companies like Alkermes, Alnylam Pharmaceuticals, bluebird bio, Idorsia Pharmaceuticals, and Moderna, as well as contract sales and contract research organizations and companies in the CP&C industries. Veeva operates as a Delaware public benefit corporation, with a stated purpose of providing products and services that help make the industries it serves more productive while creating high-quality employment opportunities, and it competes in a global, rapidly evolving market against companies including IQVIA, Oracle, OpenText, Dassault Systèmes, Honeywell, Microsoft, Salesforce, and other specialized or legacy software providers.
AI-summarized from Item 1 (Business) of the company's most recent 10-K filing.
Financials
As reported to the SEC via XBRL, no adjustments
| Gross profit | $2.41B |
| Operating income | $916.37M |
| Diluted EPS | $5.44 |
| Gross margin | 75.5% |
| Net margin | 28.4% |
Latest filings
10-K, 10-Q, 8-K, Form 4 & 13D/G. Sourced directly from SEC EDGAR
| Form | Filed | Accession |
|---|---|---|
| 4Hung Priscilla | Sep 11, 2026 | 0001628280-26-061555EDGAR |
| 4Wallach Matthew J | Sep 3, 2026 | 0001628280-26-060526EDGAR |
| 4SEKHRI PAUL J | Sep 3, 2026 | 0001628280-26-060522EDGAR |
| 4Ritter Gordon | Sep 3, 2026 | 0001628280-26-060520EDGAR |
| 4MOHR MARSHALL | Sep 3, 2026 | 0001628280-26-060518EDGAR |
| 4Hung Priscilla | Sep 3, 2026 | 0001628280-26-060516EDGAR |
| 4Hedley Mary Lynne | Sep 3, 2026 | 0001628280-26-060514EDGAR |
| 4Carges Mark T | Sep 3, 2026 | 0001628280-26-060511EDGAR |
Insider trading
From Form 4 filings
| Insider | Date | Type |
|---|---|---|
| Hung Priscilla | Sep 9, 2026 | Sell |
| Cabral Timothy S | Sep 1, 2026 | Option exercise |
| Carges Mark T | Sep 1, 2026 | Option exercise |
| Hedley Mary Lynne | Sep 1, 2026 | Option exercise |
| Hung Priscilla | Sep 1, 2026 | Option exercise |
Top holders
13F & 13D/G · latest quarter
| Holder | Stake | Filed | Value |
|---|---|---|---|
| BlackRock, Inc. | 7.9% | Aug 7, 2026 | $2.28B |
| Vanguard Capital Management | 6.0% | Aug 13, 2026 | $1.72B |
| Vanguard Portfolio Management | 4.6% | Aug 13, 2026 | $1.32B |
| STATE STREET CORPORATION | 4.1% | Aug 7, 2026 | $1.19B |
| AllianceBernstein L.P. | 3.0% | Aug 14, 2026 | $863.07M |
VEEV's filings are public. The insight is one click away.
Scrutar's AI reads every VEEV filing and surfaces what matters. Red flags, risk shifts, disclosure quality and key relationships. Cited to the source, free with an account.
Never miss a VEEV filing.
Get an email when VEEV files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Sep 15, 2026Source: SEC EDGAR.